Literature DB >> 22202151

Applications of 211At and 223Ra in targeted alpha-particle radiotherapy.

Ganesan Vaidyanathan1, Michael R Zalutsky.   

Abstract

Targeted radiotherapy using agents tagged with α-emitting radionuclides is gaining traction with several clinical trials already undertaken or ongoing, and others in the advanced planning stage. The most commonly used α-emitting radionuclides are 213Bi, 211At, 223Ra and 225Ac. While each one of these has pros and cons, it can be argued that 211At probably is the most versatile based on its half life, decay scheme and chemistry. On the other hand, for targeting bone metastases, 223Ra is the ideal radionuclide because simple cationic radium can be used for this purpose. In this review, we will discuss the recent developments taken place in the application of 211At-labeled radiopharmaceuticals and give an overview of the current status of 223Ra for targeted α-particle radiotherapy.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22202151      PMCID: PMC3368371          DOI: 10.2174/1874471011104040283

Source DB:  PubMed          Journal:  Curr Radiopharm        ISSN: 1874-4710


  63 in total

Review 1.  High-linear energy transfer irradiation targeted to skeletal metastases by the alpha-emitter 223Ra: adjuvant or alternative to conventional modalities?

Authors:  Øyvind S Bruland; Sten Nilsson; Darrell R Fisher; Roy H Larsen
Journal:  Clin Cancer Res       Date:  2006-10-15       Impact factor: 12.531

2.  Significant antitumor effect from bone-seeking, alpha-particle-emitting (223)Ra demonstrated in an experimental skeletal metastases model.

Authors:  Gjermund Henriksen; Knut Breistøl; Øyvind S Bruland; Øystein Fodstad; Roy H Larsen
Journal:  Cancer Res       Date:  2002-06-01       Impact factor: 12.701

3.  Glomerular filtration rate after alpha-radioimmunotherapy with 211At-MX35-F(ab')2: a long-term study of renal function in nude mice.

Authors:  Tom Bäck; Börje Haraldsson; Ragnar Hultborn; Holger Jensen; Martin E Johansson; Sture Lindegren; Lars Jacobsson
Journal:  Cancer Biother Radiopharm       Date:  2009-12       Impact factor: 3.099

4.  Sodium iodide symporter (NIS)-mediated radiovirotherapy for pancreatic cancer.

Authors:  Alan R Penheiter; Troy R Wegman; Kelly L Classic; David Dingli; Claire E Bender; Stephen J Russell; Stephanie K Carlson
Journal:  AJR Am J Roentgenol       Date:  2010-08       Impact factor: 3.959

5.  A kit method for the high level synthesis of [211At]MABG.

Authors:  Ganesan Vaidyanathan; Donna J Affleck; Kevin L Alston; Xiao-Guang Zhao; Marc Hens; Duncan H Hunter; John Babich; Michael R Zalutsky
Journal:  Bioorg Med Chem       Date:  2007-03-12       Impact factor: 3.641

6.  Preparation of 5-[131I]iodo- and 5-[211At]astato-1-(2-deoxy-2-fluoro-beta-D-arabinofuranosyl) uracil by a halodestannylation reaction.

Authors:  G Vaidyanathan; M R Zalutsky
Journal:  Nucl Med Biol       Date:  1998-07       Impact factor: 2.408

7.  Oncolytic measles viruses encoding interferon beta and the thyroidal sodium iodide symporter gene for mesothelioma virotherapy.

Authors:  H Li; K-W Peng; D Dingli; R A Kratzke; S J Russell
Journal:  Cancer Gene Ther       Date:  2010-04-09       Impact factor: 5.987

8.  Reagents for astatination of biomolecules. 2. Conjugation of anionic boron cage pendant groups to a protein provides a method for direct labeling that is stable to in vivo deastatination.

Authors:  D Scott Wilbur; Ming-Kuan Chyan; Donald K Hamlin; Robert L Vessella; Timothy J Wedge; M Frederick Hawthorne
Journal:  Bioconjug Chem       Date:  2007-06-21       Impact factor: 4.774

9.  Intraperitoneal alpha-particle radioimmunotherapy of ovarian cancer patients: pharmacokinetics and dosimetry of (211)At-MX35 F(ab')2--a phase I study.

Authors:  Håkan Andersson; Elin Cederkrantz; Tom Bäck; Chaitanya Divgi; Jörgen Elgqvist; Jakob Himmelman; György Horvath; Lars Jacobsson; Holger Jensen; Sture Lindegren; Stig Palm; Ragnar Hultborn
Journal:  J Nucl Med       Date:  2009-06-12       Impact factor: 10.057

10.  In vitro experimental (211)At-anti-CD33 antibody therapy of leukaemia cells overcomes cellular resistance seen in vivo against gemtuzumab ozogamicin.

Authors:  Thorsten Petrich; Zekiye Korkmaz; Doris Krull; Cornelia Frömke; Geerd J Meyer; Wolfram H Knapp
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-01-27       Impact factor: 9.236

View more
  20 in total

1.  A unique alpha dosimetry technique using Gafchromic EBT3(®) film and feasibility study for an activity calibrator for alpha-emitting radiopharmaceuticals.

Authors:  Bhaskar Mukherjee; Yaser H Gholami; Uday Bhonsle; Reinhard Hentschel; Joseph Khachan
Journal:  Br J Radiol       Date:  2015-10-06       Impact factor: 3.039

Review 2.  Radiopharmaceuticals for metastatic bone pain palliation: available options in the clinical domain and their comparisons.

Authors:  Tapas Das; Sharmila Banerjee
Journal:  Clin Exp Metastasis       Date:  2016-12-17       Impact factor: 5.150

3.  Labeling Monoclonal Antibody with α-emitting 211At at High Activity Levels via a Tin Precursor.

Authors:  Ganesan Vaidyanathan; Oscar R Pozzi; Jaeyeon Choi; Xiao-Guang Zhao; Shawn Murphy; Michael R Zalutsky
Journal:  Cancer Biother Radiopharm       Date:  2020-02-28       Impact factor: 3.099

4.  Stability and in vivo behavior of Rh[16aneS4-diol]211 at complex: a potential precursor for astatine radiopharmaceuticals.

Authors:  Marek Pruszyński; Monika Łyczko; Aleksander Bilewicz; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2014-12-23       Impact factor: 2.408

Review 5.  Targeted α-particle therapy of bone metastases in prostate cancer.

Authors:  Hossein Jadvar; David I Quinn
Journal:  Clin Nucl Med       Date:  2013-12       Impact factor: 7.794

6.  Targeted α-Therapy in Cancer Management: Synopsis of Preclinical and Clinical Studies.

Authors:  Hossein Jadvar
Journal:  Cancer Biother Radiopharm       Date:  2020-03-23       Impact factor: 3.099

7.  Radiopharmaceutical chemistry of targeted radiotherapeutics, part 4: Strategies for 211At labeling at high activities and radiation doses of 211At α-particles.

Authors:  Oscar R Pozzi; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2016-12-10       Impact factor: 2.408

8.  Synthesis and preliminary evaluation of 211At-labeled inhibitors of prostate-specific membrane antigen for targeted alpha particle therapy of prostate cancer.

Authors:  Ganesan Vaidyanathan; Ronnie C Mease; Il Minn; Jaeyeon Choi; Ying Chen; Hassan Shallal; Choong Mo Kang; Darryl McDougald; Vivek Kumar; Martin G Pomper; Michael R Zalutsky
Journal:  Nucl Med Biol       Date:  2021-01-23       Impact factor: 2.408

Review 9.  Targeted α-therapy in non-prostate malignancies.

Authors:  Hossein Jadvar; Patrick M Colletti
Journal:  Eur J Nucl Med Mol Imaging       Date:  2021-05-16       Impact factor: 9.236

10.  Stabilization of an 211At-Labeled Antibody with Sodium Ascorbate.

Authors:  Shino Manabe; Hiroki Takashima; Kazunobu Ohnuki; Yoshikatsu Koga; Ryo Tsumura; Nozomi Iwata; Yang Wang; Takuya Yokokita; Yukiko Komori; Sachiko Usuda; Daiki Mori; Hiromitsu Haba; Hirofumi Fujii; Masahiro Yasunaga; Yasuhiro Matsumura
Journal:  ACS Omega       Date:  2021-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.